Xianghua Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xianghua Luo has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey S. Miller
Department of Medicine, University of Minnesota, Minneapolis, USA
29 shared publications - Martin Felices
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
26 shared publications - Melissa Khaw
Masonic Cancer Center, University of Minnesota, Minneapolis, MN
26 shared publications - Peter Hinderlie
Masonic Cancer Center, Minneapolis, Minnesota
26 shared publications - Philippa Kennedy
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
26 shared publications - Quinlan M. Kile
Masonic Cancer Center, Minneapolis, Minnesota
26 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Wiley in British Journal of Haematology
Cytoreductive therapy reduces JAK2 V617F + blood velocity and adhesion to activated endothelium
- 20 October 2026
- Published by Wiley in British Journal of Haematology
Open AccessCytoreductive therapy reduces JAK2 V617F + blood velocity and adhesion to activated endothelium
- Open Access
- 26 August 2026
- Published by Springer Nature in BMC Medical Research Methodology
Two-sample survival probability curves: a graphical method for survival data beyond right censoring
Background: Studies with complex censoring or truncation mechanisms in survival data have historically simplified their data to use right censoring methods and to report treatment effect measures such as the hazard ratio calculated under the right-censoring mechanism. This can lead to loss of information, potential biases, and difficulties with interpretation of study results. In a previous study, we developed a graphical method called “two-sample survival probability curve” to complement current practice in treatment comparisons under right censoring and improve the communication of trial results. Methods: In this paper, we extend this novel two-sample graphical approach, which allows visualization of treatment effects and the adequacy of model fits in a [0,1] $$\times$$ [0,1] space, to the analysis of arbitrarily censored and truncated time-to-event data. We first review one-sample nonparametric maximum likelihood estimators (NPMLEs), the analog of the Kaplan-Meier estimator, for a variety of censoring and truncation mechanisms. Then we propose the two-sample survival probability curves based on these NPMLEs and perform Monte-Carlo simulations to examine their performance. Results: We demonstrate the proposed graphical method for interval censored, doubly censored, doubly interval censored, and singly truncated, singly censored data using some well-known survival data examples. An R package has been developed for our graphical method for both right censored data and the other types of censored or truncated data discussed in this paper. Conclusions: We successfully extended a novel graphical tool to complement the analysis of different types of survival data for two-sample treatment comparisons.- 26 August 2026
- Published by Springer Nature in BMC Medical Research Methodology
Open AccessTwo-sample survival probability curves: a graphical method for survival data beyond right censoring
Background: Studies with complex censoring or truncation mechanisms in survival data have historically simplified their data to use right censoring methods and to report treatment effect measures such as the hazard ratio calculated under the right-censoring mechanism. This can lead to loss of information, potential biases, and difficulties with interpretation of study results. In a previous study, we developed a graphical method called “two-sample survival probability curve” to complement current practice in treatment comparisons under right censoring and improve the communication of trial results. Methods: In this paper, we extend this novel two-sample graphical approach, which allows visualization of treatment effects and the adequacy of model fits in a [0,1] $$\times$$ [0,1] space, to the analysis of arbitrarily censored and truncated time-to-event data. We first review one-sample nonparametric maximum likelihood estimators (NPMLEs), the analog of the Kaplan-Meier estimator, for a variety of censoring and truncation mechanisms. Then we propose the two-sample survival probability curves based on these NPMLEs and perform Monte-Carlo simulations to examine their performance. Results: We demonstrate the proposed graphical method for interval censored, doubly censored, doubly interval censored, and singly truncated, singly censored data using some well-known survival data examples. An R package has been developed for our graphical method for both right censored data and the other types of censored or truncated data discussed in this paper. Conclusions: We successfully extended a novel graphical tool to complement the analysis of different types of survival data for two-sample treatment comparisons. - Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Antigen specificity test of PSMA TriKE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Antigen specificity test of PSMA TriKE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA TriKE testing against patient-derived xenograft (PDX).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA TriKE testing against patient-derived xenograft (PDX).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
MDSC phenotype and suppression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
MDSC phenotype and suppression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Healthy donors and prostate cancer patient-derived NK cell killing capacity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Healthy donors and prostate cancer patient-derived NK cell killing capacity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Reagent list for time-of-flight mass cytometry (CyTOF).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Reagent list for time-of-flight mass cytometry (CyTOF).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA abundance on C4-2 WT and C4-2 PSMA KO.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
PSMA abundance on C4-2 WT and C4-2 PSMA KO.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Calculations of equifunctional dose of IL15 compared to PSMA TriKE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Calculations of equifunctional dose of IL15 compared to PSMA TriKE.